172 related articles for article (PubMed ID: 2068160)
1. Therapeutic implications of the uptake of radiolabelled mIBG for the treatment of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Prog Clin Biol Res; 1991; 366():455-61. PubMed ID: 2068160
[No Abstract] [Full Text] [Related]
2. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
3. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
4. Iodine-125-MIBG therapy for neuroblastoma.
Hoefnagel CA; Smets L; Voûte PA; de Kraku J
J Nucl Med; 1991 Feb; 32(2):361-2. PubMed ID: 1992043
[No Abstract] [Full Text] [Related]
5. Radiolabelled mIBG in the treatment of neuroblastoma.
Gaze MN; Wheldon TE
Eur J Cancer; 1996 Jan; 32A(1):93-6. PubMed ID: 8695251
[No Abstract] [Full Text] [Related]
6. Session on the biology and treatment of neuroblastoma as related to metaiodobenzylguanidine. Chairmen's report.
Sisson JC; De Bernardi B
J Nucl Biol Med (1991); 1991; 35(4):199-201. PubMed ID: 1823818
[No Abstract] [Full Text] [Related]
7. Opioid peptides as possible cause of pain reduction in neuroblastoma after admission of 131I-meta-iodobenzylguanidine.
Klingebiel T; Bruchelt G; Kaleva N; Wollmann H; Handgretinger R; Treuner J; Gupta D; Niethammer D
Prog Clin Biol Res; 1991; 366():509-12. PubMed ID: 2068167
[No Abstract] [Full Text] [Related]
8. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
9. Results of treatment with 131 I-metaiodobenzylguanidine (131 I-MIBG) in patients with neuroblastoma. Future prospects of zetotherapy.
Voûte PA; Hoefnagel CA; de Kraker J; Valdes Olmos R; Bakker DJ; van de Kleij AJ
Prog Clin Biol Res; 1991; 366():439-45. PubMed ID: 2068157
[No Abstract] [Full Text] [Related]
10. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
11. Treatment with meta-[131I]iodobenzylguanidine and cisplatin in stage IV neuroblastoma.
Mastrangelo S; Tornesello A; Diociaiuti L; Riccardi R; Rufini V; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):69-71. PubMed ID: 9002754
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG.
Bolster AA; Hilditch TE; Wheldon TE
J Nucl Med; 1995 Aug; 36(8):1530-1. PubMed ID: 7629603
[No Abstract] [Full Text] [Related]
13. Treatment of neuroblastoma with [125I]metaiodobenzylguanidine.
Sisson JC; Shapiro B; Hutchinson RJ; Zasadny KR; Mallette S; Mudgett EE; Wieland DM
J Nucl Biol Med (1991); 1991; 35(4):255-9. PubMed ID: 1823830
[TBL] [Abstract][Full Text] [Related]
14. The treatment of neuroblastoma with [131I]MIBG at diagnosis.
Troncone L; Rufini V; Luzi S; Mastrangelo R; Riccardi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):65-8. PubMed ID: 9002753
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic use of I-131 meta-iodobenzylguanidine (mIBG) in neuroblastoma: a phase II study in 12 patients.
Hartmann O; Lumbroso JD; Lemerle M; Schlumberger M; Ricard M; Aubert B; Coornaert S; Merlin L; Parmentier C
Prog Clin Biol Res; 1988; 271():655-67. PubMed ID: 3043455
[No Abstract] [Full Text] [Related]
16. Model studies on metaiodobenzylguanidine (MIBG) uptake and storage: relevance for 131I-MIBG therapy of neuroblastoma.
Smets LA; Rutgers M
J Nucl Biol Med (1991); 1991; 35(4):191-4. PubMed ID: 1823816
[No Abstract] [Full Text] [Related]
17. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic use of I-131-MIBG in nude mice hosting human neuroblastoma xenografts.
Senekowitsch R; Laubenbacher C; Möllenstädt S; Kriegel H; Pabst HW
Strahlenther Onkol; 1989 Jul; 165(7):566-8. PubMed ID: 2749502
[No Abstract] [Full Text] [Related]
19. New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
Mairs RJ; Zalutsky MR
Br J Cancer; 1995 Jul; 72(1):250. PubMed ID: 7599061
[No Abstract] [Full Text] [Related]
20. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
